Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorJonsson Comprehensive Cancer Center

About this trial

This study evaluates how new magnetic resonance imaging (MRI) and artificial intelligence techniques improve the image quality and quantitative information for future prostate MRI exams in patients with suspicious of confirmed prostate cancer. The MRI and artificial intelligence techniques developed in this study may improve the accuracy in diagnosing prostate cancer in the future using less invasive techniques than what is currently used.

Eligibility criteria

Qualifiers

Male patients 18 years of age and older

Clinical suspicion of prostate cancer or biopsy-confirmed prostate cancer

Undergone or undergoing multi-parametric 3 T prostate MRI at the University of California at Los Angeles (UCLA)

Ability to provide consent

Disqualifiers

Contraindications to MRI (e.g., cardiac devices, prosthetic valves, severe claustrophobia)

Contraindications to gadolinium contrast-based agents other than the possibility of an allergic reaction to the gadolinium contrast-based agent

Prior radiotherapy

Trial design

Treatments tested in this trial

  • 3 Tesla Magnetic Resonance Imaging
  • Electronic Health Record Review

Treatment groups

275 Participants
are divided into 1 treatment group

Sponsors and collaborators

Jonsson Comprehensive Cancer Center

Lead sponsor

National Institutes of Health (NIH)

Collaborator

National Cancer Institute (NCI)

Collaborator